Anemia encompasses diverse disorders characterised by insufficient red-blood-cell mass or haemoglobin production, ranging from iron deficiency and chronic disease anaemia to haemolytic syndromes and bone-marrow disorders.
Anemia encompasses diverse disorders characterised by insufficient red-blood-cell mass or haemoglobin production, ranging from iron deficiency and chronic disease anaemia to haemolytic syndromes and bone-marrow disorders. Stem-cell research investigates whether placental mesenchymal stem cells and fetal stem cells can stimulate erythropoiesis, enhance iron metabolism, reduce chronic inflammation driving anaemia, and regenerate damaged haematopoietic niches. With 531 registered trials — by far the largest evidence base among studied conditions — and 83 currently recruiting, the scope encompasses both direct support of erythroid progenitors and paracrine reduction of inflammatory barriers to red-cell production. The diversity of anaemia aetiologies means that stem-cell approaches must be matched to underlying pathophysiology: supportive in chronic renal disease, immunomodulatory in autoimmune haemolytic anaemia, regenerative in aplastic anaemia.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €5,000–€25,000 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Fetal Stem Cells |
| Approval status | Approved (blood/immune only) |
| Registered trials (ClinicalTrials.gov) | 531 · 83 recruiting now |
For the clinic's own description, see how Stem Plus describes its Anemia programme ↗.
Anemia trials represent the largest stem-cell research cohort, reflecting disease prevalence and unmet medical need. Trial outcomes vary substantially by anaemia type. In aplastic anaemia and myelodysplastic syndrome cohorts, MSC infusion has supported haematopoietic recovery, with some patients achieving transfusion-independence. In chronic kidney disease anaemia, paracrine effects of MSCs may enhance endogenous erythropoietin responsiveness. Autoimmune haemolytic anaemia trials report reduced haemolysis markers and improved haemoglobin in responsive patients. However, heterogeneous trial designs, small sample sizes, and variable control arms limit systematic comparison. Eighty-three recruiting trials suggest ongoing clinical momentum, though few have advanced to Phase 3 efficacy endpoints. Long-term haematological stability post-treatment remains incompletely characterised.
Depending on assessment, a Anemia protocol may draw on:
Anemia stem-cell treatment costs range widely, typically €3,000–7,000 per cycle, reflecting the diversity of anaemia types and infusion protocols. Bone-marrow-targeted injection or systemic intravenous administration influence cost structure. Placental MSCs are favoured for cost-efficiency; fetal stem-cell approaches, when used, incur higher sourcing and manufacturing expenses. Repeat infusions are common in anaemia protocols; multi-cycle treatment plans may exceed €15,000 total. Peripheral European centres (Poland, Czech Republic) typically charge €3,000–4,500; Western European and private boutique clinics charge €5,000–8,000. Auxiliary testing — complete blood counts, reticulocyte counts, serology — adds modest expense but is essential to measure response.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Anemia cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Anemia.
Full Anemia FAQ → · Anemia cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
طب تجديدي معتمد GMP في قلب الاتحاد الأوروبي — من 3,000 إلى 8,000 يورو، جزء بسيط من أسعار أمريكا أو ألمانيا. بروتوكولات مخصصة لمرضى من أكثر من 50 دولة.
مراجعة طبية مجانية